Induction Chemotherapy, FOLFIRINOX Followed With Concurrent Capecitabine and Radiation Therapy in Inoperable Locally Advanced Cancer of the Pancreas

December 5, 2014 updated by: Ahmed Allam Abdelhamed Mohamed, Assiut University

Induction Chemotherapy, Fluorouracil, Leucovorin, Oxaliplatin and Irinotecan (FOLFIRINOX) Followed With Concurrent Capecitabine and Radiation Therapy in Treatment of Patients With Inoperable Locally Advanced Cancer Pancreas

This prospective cohort, phase II, trial is studying induction chemotherapy combination, FOLFIRINOX regimen, consisted of oxaliplatin, irinotecan, leucovorin and fluorouracil (5-FU), for 4 cycles, followed by consolidation concurrent radiotherapy with capecitabine in non-progressed cases, in treating patients with locally advanced cancer pancreas.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

Design & Methodology:

  1. Nature of the study:

    It is ( prospective cohort study).

  2. Study subjects:

    *Target Population: Patients, fulfilling the inclusion criteria for the research, will be selected from Assiut clinical oncology department in Assiut University Hospitals.

    • Sample size:

      20 patients.

    • Characteristics of subjects:

      • Inclusion criteria:

    Disease characteristics:

    • Histological and radiological confirmation of locally advanced cancer pancreas
    • Inoperable disease
    • Disease must be able to be encompassed within a radical radiotherapy treatment volume
    • Not metastatic

    Patient characteristics:

    • ECOG performance status 0 or 1
    • Life expectancy > 3 months.
    • Glomerular filtration rate ≥ 60 mL/min.
    • WBC > 3,000/mm³.
    • Absolute neutrophil count > 1,500/mm³.
    • Hemoglobin > 10.0 g/dL.
    • Platelet count > 100,000/mm³.
    • Alkaline phosphatase ≤ 1.5 times upper limit of normal (ULN)
    • Gamma-glutamyl-transferase < 1.5 times ULN.
    • Transaminases ≤ 1.5 times ULN.
    • Bilirubin ≤ 1.5 times ULN.
    • No medically unstable conditions (e.g., unstable diabetes, uncontrolled arterial hypertension, infection, hypercalcemia, or ischemic heart disease)
    • Not pregnant or nursing.
    • No other previous or current malignant disease likely to interfere with protocol treatment or comparisons
    • No prior chemotherapy or radiotherapy.
  3. Patients & Methods:

    Patients are randomized to one treatment arm. Induction 4 times chemotherapy, FOLFIRINOX regimen, consisted of Oxaliplatin at a dose of 85 mg/m2 on day 1 only, administered as a 2-hour intravenous infusion, with the addition, after 30 minutes, of Irinotecan at a dose of 180 mg/m2 on day 1 only given as a 90-minute intravenous infusion. immediately will be followed by Leucovorin at a dose of 200 mg/m2, given as a 2- hour intravenous infusion, day 1 and day 2 This treatment will be followed by fluorouracil (5-FU) dosed at 400 mg/m2, administered as an intravenous bolus on day 1 and day 2, followed by a continuous intravenous infusion of 600 /m2 over a 20- hours period on day 1 and day 2. Treatment will be administered every 2 weeks. G-CSF will be administrated according to the need.

    In non-progressed cases, induction chemotherapy will be followed by consolidation radiotherapy concurrent with capecitabine 625 mg/m2 BID.

    Radiotherapy :

    A fractionated dose of 50.4Gy /28 fraction/15 MeV photon energy generated by Dual-energetic Linear Accelerator.

    • Gross Target Volume (GTV): visible tumor and lymph nodes.
    • Clinical Target Volume (CTV): [tumor/ affected lymph node + 1-2 cm] + regional lymphatics Lymphatics :corpus: upper and lower pancreaticoduodenal, superior and inferior pancreatic, celiac Head: corpus lymphatics + porta hepatis lymphatics Tail: corpus lymphatics (except pancreaticoduodenal LN) + splenic hilum LN
    • PTV: CTV + 1-1.5 cm

      • All patients will undergo a complete classical evaluation at the time of presentation which will be enrolled in a separate sheet for each patient. This will include a detailed history with estimation of the age of onset, the duration of the disease,.
      • Detailed physical examination will be carried out Treatment evaluation . Laboratory examination include
      • complete blood count (CBC),
      • liver function test (LFT)
      • Renal function test (RFT),
      • Serum electrolytes at presentation and before each cycle of chemotherapy.

    Radiographic examination include

    • Abdominal Multi Detector Computed Tomography (MDCT Abdomen )
    • Chest X-ray Before starting treatment, 2 weeks after ending phase 1 of treatment then 4 weeks after ending phase 2 of treatment then every 3 months for 18 months.

      ● Bone scan will be done in those complaining from bone pain; elevated serum alkaline phosphatase or transaminase level

    • Quality of life is assessed at baseline, monthly for 6 months, and then at each follow-up visit.

    After completion of study treatment, patients are followed periodically. Response Assessment : will be carried out, using (RECIST) Response Evaluation Criteria In Solid Tumors, Version 1.1 Chemotherapy Toxicity Assessment: will be carried out, using (CTCAE) Common Terminology Criteria for Adverse Events, Version 4.0

  4. Data analysis:

Data will be analysed using the computer program, Statistical Package for the Social Science (SPSS V.16).

Expected outcomes:

The outcome of the study will be compared statistically with previous local and international trails.

Ethical considerations:

  1. Risk-benefit assessment:

    There is an acceptable risk may affect the patient in this research study as regard the acceptable side effects of Gemcitabine, Oxaliplatin and radiotherapy.

  2. Confidentiality:

    Any data taken from the patient either from history, the examination or the investigations will be very confidential.

  3. Research statement:

    All patients subjected to this study will be informed about the procedures of the research.

  4. Informed consent:

    The study procedures will be discussed to all patients and consent will be taken from them.

  5. Other ethical concerns:

The research will be conducted only by scientifically qualified and trained personnel.

Study Type

Interventional

Enrollment (Anticipated)

1

Phase

  • Phase 2
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Disease characteristics:

    • Histological and radiological confirmation of locally advanced cancer pancreas
    • Inoperable disease
    • Disease must be able to be encompassed within a radical radiotherapy treatment volume
    • Not metastatic

Patient characteristics:

  • ECOG performance status 0 or 1
  • Life expectancy > 3 months.
  • Glomerular filtration rate ≥ 60 mL/min.
  • WBC > 3,000/mm³.
  • Absolute neutrophil count > 1,500/mm³.
  • Hemoglobin > 10.0 g/dL.
  • Platelet count > 100,000/mm³.
  • Alkaline phosphatase ≤ 1.5 times upper limit of normal (ULN)
  • Gamma-glutamyl-transferase < 1.5 times ULN.
  • Transaminases ≤ 1.5 times ULN.
  • Bilirubin ≤ 1.5 times ULN.
  • No medically unstable conditions (e.g., unstable diabetes, uncontrolled arterial hypertension, infection, hypercalcemia, or ischemic heart disease)
  • Not pregnant or nursing.
  • No other previous or current malignant disease likely to interfere with protocol treatment or comparisons
  • No prior chemotherapy or radiotherapy.

Exclusion Criteria:

  • ECOG performance status > 2
  • Life expectancy < 3 months.
  • Glomerular filtration rate < 30 mL/min.
  • Absolute neutrophil count < 1,500/mm³.
  • Alkaline phosphatase > 1.5 times upper limit of normal (ULN)
  • Gamma-glutamyl-transferase > 1.5 times ULN.
  • Transaminases>1.5 times ULN.
  • Bilirubin >1.5 times ULN.
  • medically unstable conditions (e.g., unstable diabetes, uncontrolled arterial hypertension, infection, hypercalcemia, or ischemic heart disease)
  • pregnant or nursing.
  • prior chemotherapy or radiotherapy.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: FOLFIRINOX + CRT
FOLFIRINOX regimen, consisted of oxaliplatin, irinotecan, leucovorin and fluorouracil (5-FU), for 4 cycles, followed by consolidation radiotherapy concurrent with capecitabine 625mg/m2 BID in non-progressed cases, in treating patients with locally advanced cancer pancreas.

Induction 4 times chemotherapy, FOLFIRINOX regimen, consisted of Oxaliplatin at a dose of 85 mg/m2 D1, 2-hour I.V + Irinotecan 180 mg/m2 D1 90-minute I.V. + Leucovorin 200 mg/m2 2- hour I.V, D1,2 + (5-FU) dosed at 400 mg/m2, administered as an intravenous bolus on day 1 and day 2, followed by a continuous intravenous infusion of 600 /m2 over a 20- hours period on day 1 and day 2. Treatment will be administered every 2 weeks. G-CSF will be administrated according to the need.

In non-progressed cases, will be followed by consolidation concurrent radiotherapy with capecitabine 625 mg/m2 BID.

Radiotherapy :

A fractionated dose of 50.4Gy /28 fractions/15 MeV photon energy generated by Dual-energetic Linear Accelerator.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of Participants with Adverse Events as a Measure of Safety and Tolerability of FOLFIRINOX plus Concurrent Radiotherapy with Capecitabine
Time Frame: 6 months after enrolment
will be carried out, using (CTCAE) Common Terminology Criteria for Adverse Events, Version 4.0
6 months after enrolment

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Tumor response
Time Frame: 6 months after enrolment
will be carried out, using (RECIST) Response Evaluation Criteria In Solid Tumors, Version 1.1
6 months after enrolment

Other Outcome Measures

Outcome Measure
Time Frame
Progression Free Survival
Time Frame: 6 months after finishing protocol
6 months after finishing protocol
Number of Cases will have radical surgery
Time Frame: 6 months after enrolment
6 months after enrolment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2014

Primary Completion (Anticipated)

November 1, 2016

Study Completion (Anticipated)

April 1, 2017

Study Registration Dates

First Submitted

December 4, 2014

First Submitted That Met QC Criteria

December 5, 2014

First Posted (Estimate)

December 8, 2014

Study Record Updates

Last Update Posted (Estimate)

December 8, 2014

Last Update Submitted That Met QC Criteria

December 5, 2014

Last Verified

December 1, 2014

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe